4-amino-3,5-diisopropylphenol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-amino-3,5-diisopropylphenol
• 英文别名: 4-amino-3,5-di(propan-2-yl)phenol
• 化学式: C₁₂H₁₉NO
• 分子量: 193.289
• InChiKey: IGACATZUSHRAIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-amino-3,5-diisopropylphenol 在 甲酸 、 四丁基碘化铵 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙醇 、 甲苯 为溶剂， 反应 58.75h， 生成 1,3-bis[4-(3-butenyloxy)-2,6-diisopropylphenyl]imidazolium chloride
  参考文献：
  名称：

  功能化可烷氧基连接的N-杂环碳原子配体的模块化合成和用于布赫瓦尔德-哈特维格胺胺化的活性催化剂

  摘要：

  AbstractModular syntheses of functionalised, alkoxy‐tethered 1,3‐bis(2,4,6‐trimethylphenyl)imidazolium (IMes⋅H+) and 1,3‐bis(2,6‐diisopropylphenyl)imidazolium (IPr⋅H+) derivatives 1,3‐bis(4‐alkyloxy‐2,4,6‐trimethylphenyl)imidazolium (IXyOR⋅H+) and 1,3‐bis(4‐alkyloxy‐2,6‐diisopropylphenyl)imidazolium (IPrOR⋅H+) are reported. A reliable synthesis of the key starting material 4‐amino‐3,5‐diisopropylphenol is also described. Etherification of hydroxy‐decorated ligand intermediates before formation of the imidazolium core and subsequent modification, or direct etherification of the versatile synthon IPrOH⋅HCl, allowed access to various linker types including triethoxysilyl, primary amino and norbornenyl, which are not accessible by other methods. An IPrOR–palladium(II) complex was prepared, and its catalytic activity was evaluated in challenging Buchwald–Hartwig aminations of aryl chlorides. This precatalyst displayed excellent activity and selectivity under mild reaction conditions, achieving in some cases a 10‐fold improvement in TOF relative to the IPr‐based version. An unexpected activity profile was observed wherein sterically demanding anilines were coupled more easily than those lacking ortho‐substitution.magnified image

  DOI：

  10.1002/adsc.201300903
• 作为产物：
  描述：

  2,6-diisopropylnitrobenzene 在 硫酸 、 氯化铵 作用下， 以 乙醚 、 水 、 丙酮 为溶剂， 反应 17.67h， 生成 4-amino-3,5-diisopropylphenol
  参考文献：
  名称：

  功能化可烷氧基连接的N-杂环碳原子配体的模块化合成和用于布赫瓦尔德-哈特维格胺胺化的活性催化剂

  摘要：

  AbstractModular syntheses of functionalised, alkoxy‐tethered 1,3‐bis(2,4,6‐trimethylphenyl)imidazolium (IMes⋅H+) and 1,3‐bis(2,6‐diisopropylphenyl)imidazolium (IPr⋅H+) derivatives 1,3‐bis(4‐alkyloxy‐2,4,6‐trimethylphenyl)imidazolium (IXyOR⋅H+) and 1,3‐bis(4‐alkyloxy‐2,6‐diisopropylphenyl)imidazolium (IPrOR⋅H+) are reported. A reliable synthesis of the key starting material 4‐amino‐3,5‐diisopropylphenol is also described. Etherification of hydroxy‐decorated ligand intermediates before formation of the imidazolium core and subsequent modification, or direct etherification of the versatile synthon IPrOH⋅HCl, allowed access to various linker types including triethoxysilyl, primary amino and norbornenyl, which are not accessible by other methods. An IPrOR–palladium(II) complex was prepared, and its catalytic activity was evaluated in challenging Buchwald–Hartwig aminations of aryl chlorides. This precatalyst displayed excellent activity and selectivity under mild reaction conditions, achieving in some cases a 10‐fold improvement in TOF relative to the IPr‐based version. An unexpected activity profile was observed wherein sterically demanding anilines were coupled more easily than those lacking ortho‐substitution.magnified image

  DOI：

  10.1002/adsc.201300903

文献信息

• Novel cyclic diamine compounds and medicine containing the same
  申请人：Kowa Company, Ltd.

  公开号：US20040038987A1

  公开（公告）日：2004-02-26

  The present invention offers novel cyclic diamine compounds and a pharmaceutical composition containing the same. The present invention relates to a compound represented by the formula (I) or salt(s) or solvate(s) thereof. 1 (In the formula, 2 is an optionally substituted divalent residue of benzene, pyridine, cyclohexane or naphthalene or is a vinylene group where Ar is an optionally substituted aryl group; X is —NH—, oxygen atom or sulfur atom; Y is —NR 1 —, oxygen atom, sulfur atom, sulfoxide or sulfone; Z is a single bond or —NR 2 —; R 1 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group; R 2 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group; l is an integer of from 0 to 15; m is an integer of 2 or 3; and n is an integer of from 0 to 3). The compound of the present invention is useful as a pharmaceutical composition, particuarly as an inhibitor of acyl coenzyme A cholesterol acyltransferase (ACAT).

  本发明提供了新颖的环状二胺化合物以及含有该化合物的药物组合物。本发明涉及由式(I)表示的化合物或其盐或溶剂化合物。(在该式中，2是苯、吡啶、环己烷或萘的可选择取代的二价残基，或者是Ar为可选择取代芳基的乙烯基；X为—NH—、氧原子或硫原子；Y为—NR1—、氧原子、硫原子、亚砜或砜；Z为单键或—NR2—；R1为氢原子、可选择取代的较低烷基、可选择取代的芳基或可选择取代的硅烷较低烷基；R2为氢原子、可选择取代的较低烷基、可选择取代的芳基或可选择取代的硅烷较低烷基；l为0到15的整数；m为2或3的整数；n为0到3的整数)。本发明的化合物可用作药物组合物，特别是作为酰辅酶A胆固醇酰基转移酶(ACAT)的抑制剂。
• Cyclic diamine compounds and medicine containing the same
  申请人：Shibuya Kimiyuki

  公开号：US06969711B2

  公开（公告）日：2005-11-29

  The present invention offers novel cyclic diamine compounds and a pharmaceutical composition containing the same. The present invention relates to a compound represented by the formula (I) or salt(s) or solvate(s) thereof. (In the formula, is an optionally substituted divalent residue of benzene, pyridine, cyclohexane or naphthalene or is a vinylene group where Ar is an optionally substituted aryl group; X is —NH—, oxygen atom or sulfur atom; Y is —NR 1 —, oxygen atom, sulfur atom, sulfoxide or sulfone; Z is a single bond or —NR 2 —; R 1 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group; R 2 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group; l is an integer of from 0 to 15; m is an integer of 2 or 3; and n is an integer of from 0 to 3). The compound of the present invention is useful as a pharmaceutical composition, particuarly as an inhibitor of acyl coenzyme A cholesterol acyltransferase (ACAT).

  本发明提供了新颖的环状二胺化合物以及含有该化合物的药物组合物。本发明涉及一种由式(I)表示的化合物或其盐或溶剂化合物。(在该式中，是苯、吡啶、环己烷或萘的可选择取代的二价残基，或者是一种乙烯基团，其中Ar是可选择取代的芳基；X是—NH—、氧原子或硫原子；Y是—NR1—、氧原子、硫原子、亚氧化物或砜；Z是单键或—NR2—；R1是氢原子、可选择取代的较低烷基团、可选择取代的芳基或可选择取代的硅烷较低烷基团；R2是氢原子、可选择取代的较低烷基团、可选择取代的芳基或可选择取代的硅烷较低烷基团；l是0到15的整数；m是2或3的整数；n是0到3的整数)。本发明的化合物可用作药物组合物，特别是作为酰辅酶A胆固醇酰基转移酶(ACAT)的抑制剂。
• VASCULAR WALL-SELECTIVE ACAT INHIBITOR
  申请人：Kowa Company Ltd.

  公开号：EP1431294A1

  公开（公告）日：2004-06-23

  It is intended to provide a novel compound, which sustains an ACAT inhibitory activity and a macrophage-selectivity to a certain degree as a practically usable drug and can maintain an excellent oral absorption property and a favorable drug concentration in case of tested in vivo; a process for producing the same; medicinal compositions comprising the same and its intermediate. Namely, 2-[4-[2-(7-trifuoromethylbenzoxazol-2-ylthio)-ethyl]piperazin-1-yl]-N-(2,6-diisopropyl-4-hydroxyphenyl)-acetamide represented by the following formula: salts thereof or solvates of the same; and medicinal compositions comprising the compound represented by the above formula, salts thereof or solvates of the same together with pharmaceutically acceptable carriers.

  本发明旨在提供一种新型化合物，该化合物具有抑制ACAT活性和对巨噬细胞选择性在一定程度上作为一种实用药物，并且在体内测试时能够保持出色的口服吸收性能和有利的药物浓度；以及生产该化合物的方法；包含该化合物及其中间体的药用组合物。即以下式所示的2-[4-[2-(7-三氟甲基苯并噁唑-2-基硫基)-乙基]哌嗪-1-基]-N-(2,6-二异丙基-4-羟基苯基)-乙酰胺：其盐或其溶剂；以及包含上述式所代表的化合物、其盐或其溶剂以及药用可接受载体的药用组合物。
• Redox‐Neutral Nickel(II) Catalysis: Hydroarylation of Unactivated Alkenes with Arylboronic Acids
  作者：Dao‐Ming Wang、Wang Feng、Yichen Wu、Tao Liu、Peng Wang

  DOI：10.1002/anie.202009195

  日期：2020.11.9

  additional oxidants and reductants. Mechanistic investigations using kinetic analysis and deuterium‐labelling experiments revealed the protonation to be the rate‐determining step in this redox‐neutral catalysis, and the reversible chain‐walking nature of the newly developed diimine‐Ni catalyst.

  此处报道的是氧化还原中性Ni II / Ni II催化循环的发现，该催化循环首次能够将未活化烯烃与芳基硼酸进行线性选择性加氢芳基化。这种新颖的催化循环可通过使用富电子的二亚胺配体实现，具有广泛的底物范围，并且在温和的反应条件下，在没有其他氧化剂和还原剂的情况下具有出色的官能团和杂环相容性。使用动力学分析和氘标记实验的机理研究表明，质子化是该氧化还原中性催化的速率决定步骤，也是新开发的二亚胺-Ni催化剂的可逆链走性质。
• COMPOUND AND POLYMER COMPOUND CONTAINING THE COMPOUND
  申请人：JAPAN SCIENCE AND TECHNOLOGY AGENCY

  公开号：US20210002284A1

  公开（公告）日：2021-01-07

  Provided is a compound having higher fluorescence quantum yield and higher optical stability than a conventional FLAP and a polymer compound containing the compound. A: seven or eight-membered ring structure, Y 1 ,Y 2 ,Y 3 : halogen atom or the like, a1: number of Y 1 , a2: number of Y 2 , B: number of Y 3 , 0≤m and n≤3: when 1≤m≤3, Y 1 may be substituted with a structure portion defined by m, when 1≤n≤3, Y 2 may be substituted with a structure portion defined by n, and B 1 , B 2 : Formulas (2-1) to (2-3). C 1 , C 2 , C 3 : structure containing a cyclic hydrocarbon compound, D 1 , D 2 , D 3 : substructure that inhibits aggregation, E 1 , E 2 , E 3 : polymerizable substructure, Z 1 : hydrogen atom or the like, c: number of substituent groups Z 1 , Z 2 , Z 3 : hydrogen atom or the like, and may form a ring with C 2 .

  提供了一种具有比传统FLAP具有更高荧光量子产率和更高光学稳定性的化合物，以及含有该化合物的聚合物化合物。A：七元或八元环结构，Y1，Y2，Y3：卤素原子或类似物，a1：Y1的数量，a2：Y2的数量，B：Y3的数量，0≤m和n≤3：当1≤m≤3时，Y1可能被定义为m的结构部分替代，当1≤n≤3时，Y2可能被定义为n的结构部分替代，B1，B2：公式（2-1）至（2-3）。C1，C2，C3：含有环烃化合物的结构，D1，D2，D3：抑制聚集的亚结构，E1，E2，E3：可聚合的亚结构，Z1：氢原子或类似物，c：取代基Z1的数量，Z2，Z3：氢原子或类似物，可能与C2形成环。